The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Yield
4.67%
Dividend safety
N/A
Growth score
N/A
Dividend growth last 5 y.
4% / year
Market Cap
112 billion
PE Ratio
16.02 x
Beta (volatility)
0.37
Earnings Per Share
5.24
About
ISIN : FR0000120578
It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare...
Price
Performance Comparison
| Sanofi S.A. | |
|---|---|
| 1 year return |
-6 %
|
| 5 years return |
+27 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 1.43 | 75 % | 0.76 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 2.44 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
18 years
Frequency
1x / year
Dividends in 2024
May
Dividends in 2023
May
May
Dividends in 2023
May
Forward Annual Amount
€3.92
Ex-dividend
5/12/2025
Financials
Year-over-Year growth
Profitability
Health
News
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
12/18/2025
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades
12/17/2025
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
12/17/2025
Press release: Availability of the Q4 2025 Aide memoire
12/17/2025
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
12/17/2025
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
12/16/2025
Market update
12/16/2025
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
12/16/2025
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
12/16/2025
Health Care Roundup: Market Talk
12/15/2025
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
12/15/2025
Sanofi, Dren Bio Collaborate on Next-Gen B-Cell Therapy for Autoimmune Diseases
12/15/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2025 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.